Oruka Therapeutics, Inc. (ORKA)
NASDAQ: ORKA · Real-Time Price · USD
15.30
+1.35 (9.68%)
At close: Aug 13, 2025, 4:00 PM
15.33
+0.03 (0.20%)
After-hours: Aug 13, 2025, 4:10 PM EDT

Oruka Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2024
Period Ending
Jun '25 Dec '24
Selling, General & Admin
19.2614.25
Research & Development
101.1681.01
Operating Expenses
120.4295.26
Operating Income
-120.42-95.26
Interest Expense
-0.64-1.6
Interest & Investment Income
14.346.4
Other Non Operating Income (Expenses)
-00
EBT Excluding Unusual Items
-106.72-90.46
Other Unusual Items
-0.87-0.87
Pretax Income
-107.59-91.34
Net Income
-107.59-91.34
Preferred Dividends & Other Adjustments
-30.15-20.39
Net Income to Common
-77.43-70.95
Shares Outstanding (Basic)
3617
Shares Outstanding (Diluted)
3617
EPS (Basic)
-2.14-4.23
EPS (Diluted)
-2.14-4.23
Free Cash Flow
-96.16-63.3
Free Cash Flow Per Share
-2.66-3.77
EBITDA
--95.23
D&A For EBITDA
-0.03
EBIT
-120.42-95.26
Updated Mar 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q